CPC Main Group Additional Only
C07K 2317/00 Immunoglobulins specific features
Filing statistics
CPC C07K 2317/00 belongs to the parent subclass C07K, which recorded 553,807 patent applications worldwide between 2013 and 2023. Annual filings grew from 35,543 in 2013 to 47,309 in 2023 (+33%), peaking at 62,417 applications in 2021. The most active applicants in class C07 are ROCHE (12,683 applications), NOVARTIS (10,775 applications) and CHINESE ACADEMY OF SCIENCES (10,619 applications).
Source: EPO PATSTAT, worldwide filings
9 direct subcodes
Child Classifications
Navigate with arrow keys, Enter to open
- C07K 2317/10 characterized by their source of isolation or production
- C07K 2317/20 characterized by taxonomic origin
- C07K 2317/30 characterized by aspects of specificity or valency
- C07K 2317/40 characterized by post-translational modification
- C07K 2317/50 characterized by immunoglobulin fragments
- C07K 2317/60 characterized by non-natural combinations of immunoglobulin fragments
- C07K 2317/70 characterized by effect upon binding to a cell or to an antigen
- C07K 2317/80 remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
- C07K 2317/90 characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Top Applicants
Top 10 applicants by patent filingsfor class C07, 2013–2023, worldwide · Source: EPO PATSTAT
- ROCHE CH 12,683
- NOVARTIS CH 10,775
- CHINESE ACADEMY OF SCIENCES 10,619
- BASF (BADISCHE ANILIN & SODA FABRIK) DE 9,511
- REGENERON PHARMACEUTICALS US 8,426
- BRISTOL-MYERS SQUIBB COMPANY US 7,979
- LG CHEM KR 7,978
- HARVARD UNIVERSITY US 7,706
- UNIVERSITY OF CALIFORNIA US 7,455
- SINOPEC (CHINA PETROCHEMICAL CORPORATION) 7,219